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Autoantibodies are valuable biomarkers for the clinical re-
search of systemic autoimmune diseases (SARD).1 The screen-
ing for antinuclear antibodies (ANA) is frequently performed 
using the classic technique of indirect immunofluorescence 
assay on HEp-2 cells (HEp-2 ANA assay). The HEp-2 ANA assay 
is recommended by the American College of Rheumatology as 
the gold standard test for autoantibody screening.2 The popu-
larization and expansion in the use of this test by several spe-
cialists, for the past 15 years or so, have caused anxiety and 
perplexity in several cases in which a positive test does not 
match the clinical presentation. Some specialists in the field 
have suggested that the correct interpretation of the HEp-2 
ANA pattern is helpful to differentiate a positive test in auto-
immune and non-autoimmune individuals. In particular, the 
Brazilian group has taken the lead on building a nation-wide 
consensus of the ANA pattern nomenclature classification. 
This initiative has been successful and related programs have 
been developed in other parts of the world. On this issue, the 
journal brings the proceedings of the fourth Brazilian Con-
sensus on ANA Pattern Nomenclature. 
The charisma of the ANA-HEp-2 test
Probably due to historical reasons, the ANA test has gained a 
very strong reputation among clinicians and nonprofession-
als. This may be partially understood if we revisit the 1960s and 
1970s scenario when medical science began to understand 
the potential diagnostic role of autoantibodies. Autoantibod-
ies were initially identified in SARD. Specifically, rheumatoid 
factor was identified as a marker for rheumatoid arthritis,3 
and the LE cell phenomenon was linked to systemic lupus 
erythematosus (SLE).4 Soon it was realized that the basis for 
the LE cell phenomenon was the reaction of autoantibodies 
against deoxyribonucleoprotein (equivalent to what we call 
nowadays anti-nucleosome or anti-chromatin antibodies). 
The early indirect immunofluorescence assays of antinuclear 
antibodies (ANA) were performed on animal tissue sections 
and they showed  limited sensitivity and a restricted array of 
immunofluorescence patterns. Nevertheless, the indirect im-
munofluorescence ANA assay soon replaced the LE Cell test 
and was included as one of the classification criteria for SLE.5 
One important aspect to be considered is that the ANA test 
was ordered mostly by rheumatologists, nephrologists, and der-
matologists; usually to test patients with high diagnostic prob-
ability for SLE. The high accuracy in the ANA results related to 
the pre-test probability, contributed to a favorable evaluation of 
the test. It is no surprise, therefore, that the ANA test achieved 
a prominent reputation as a useful specific diagnostic assay for 
SLE and related diseases. 
In the 1980s there was a shift to HEp-2 cells as substrate for 
the assay. This added a whole new dimension to the ANA test 
due to the fact that it added a higher sensitivity and a vast ar-
ray of new immunofluorescence patterns. It was progressively 
realized that, in addition to the nucleus itself, there were dozens 
of patterns associated with other cell compartments; including 
the nucleolus, cytoplasm, nuclear membrane, and mitotic ap-
paratus. The monolayer cultures of HEp-2 cells offered a unique 
display of the several cellular domains integrated to the immu-
nofluorescence system. The charming images obtained in the 
HEp-2 ANA assay definitely contributed the charisma of the test. 
One important consequence of this shift was that autoanti-
bodies associated with a larger spectrum of autoimmune dis-
eases, within and beyond rheumatology, were  readily detected 
in the HEp-2-ANA test. As a consequence, a broader group of 
physicians started ordering the test.
The idiopathic positive ANA syndrome
Contrast between reality and reputation-based expectation is 
not infrequent, and this is also true for parameters used in 
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medicine for diagnosis and for the management of patients. 
In fact, contrast is precisely what we are dealing with today at 
the HEp-2 ANA testing. Nothing can be more unrealistic than 
the idea that a positive HEp-2 ANA test is a specific evidente 
for the diagnosis of SLE, or any other systemic autoimmune 
disease. However, this misconception is firmly embedded 
in the minds of many physicians and patients for the very 
reasons exposed in the previous section. In the case of the 
HEp-2 ANA test, the contrast comes from several factors that, 
include the shifts in assay sensitivity, the clinical scenario in 
which the test is ordered, and the phenomenon of bias due to 
a generalization of the scientific observations. 
The HEp-2 ANA test proved to be much more sensitive 
than the LE cell assay and the rodent tissue-based ANA test. 
The gain in sensitivity was accompanied by a loss in specifici-
ty since a positive HEp-2 ANA test may be obtained in patients 
with several inflammatory conditions, such as infectious and 
neoplastic diseases, as well as  in apparently healthy individ-
uals.  Several studies have consistently shown that a positive 
HEp-2 ANA test occurs in 13 to 20% of the normal population 
in relation to gender and age.6,7 But at the same time, the HEp-
2 ANA test has become more and more popular among sev-
eral other specialists. Currently this test is ordered oftenly by 
gynecologists, neurologists, internists, psychiatrists, ENT spe-
cialists, dermatologists, gastroenterologists and pulmonolo-
gists  among others.8 The widespread use of the test results in 
a low pre-test trust.9 The consequence of the relatively high 
frequency of  positive HEp-2 ANA test in non-SARD patients 
plus its widespread use is a high number of “false-positive” 
results. This phenomenon has been described as the idio-
pathic positive ANA syndrome. 
The idiopathic positive ANA syndrome is a double-edged 
sword. Many patients with muscle-skeletal complaints and 
other symptoms that may be associated to SARD have the op-
portunity to be seen by a rheumatologist because of a positive 
ANA result ordered by the general practitioner or other con-
sultant. However, much stress and confusion has been caused 
by  positive ANA results in individuals with no evidence of 
SARD, or in patients with an ill-defined clinical evaluation. 
Physicians often face difficulty in interpreting a positive ANA 
test in such circumstances.
The stethoscope and the three dimensions of the 
HEp-2 ANA test
Cardiac murmurs are well known signs of heart disease and 
are carefully investigated in the clinical examination. How-
ever, it is widely acknowledged that not all murmurs are 
clinically significant. In fact, it is well recognized that many 
healthy individuals present some form of heart murmur. To 
help in the interpretation of heart auscultation, there is a wide 
collection of parameters that need to be taken into consider-
ation. For example, a low-intensity mild meso systolic mur-
mur heard at the fourth intercostal space adjacent to the left 
sternal border in a 7-year old boy is probably meaningless as 
opposed to a rough diastolic murmur with pre-systolic surge 
heard at the heart apex in a 30 year-old woman. Trained car-
diologists and internists will pay attention to these nuances 
and make decisions about further investigation accordingly. 
Similarly to the HEp-2 ANA test, the stethoscope and the 
heart auscultation procedure represent a quite charismatic 
aspect in Medicine. However, charisma is not the only feature 
in common between the stethoscope and the HEp-2 ANA test. 
As in the heart auscultation, a multitude of nuances are avail-
able for interpretation in the HEp-2 ANA test. These aspects 
can be divided into three dimensions. The careful analysis of 
these offers a useful guide for the correct interpretation of 
this serological evaluation. The first and most obvious one is 
the qualitative result: negative or positive. The second one, 
also quite intuitive, is semi quantitative and refers to the 
concentration of autoantibodies in the analyzed sample. This 
dimension is usually expressed as the titer and reactivity of 
antibodies. A higher titer means the higher the concentration 
of autoantibodies in the sample. The intuitive rationale that a 
higher titer is more clinically relevant than a lower titer HEp-
2 ANA results is generally correct, however there are several 
exceptions that make this a very relative rule. In fact, there 
are healthy individuals with a positive HEp-2 ANA test at dilu-
tions as high as 1/5.120, as well as SLE patients with a positive 
test results with low titer, such as 1/80 or 1/160. 
The third dimension of the HEp-2 ANA test refers to the 
immunofluorescence pattern and offers a very rich collec-
tion of information. It reflects the topographic distribution 
of the antigens recognized by the autoantibodies present in 
the sample. The several autoantigens have specific distribu-
tion patterns within the cell and this relationship is enriched 
if one analyzes the dynamic behavior along the successive 
stages of the cell cycle. The careful analysis of the immuno-
fluorescence pattern frequently allows to suggest certain au-
toantibody specificities with variable degrees of confidence. 
However, not all immunofluorescence patterns allow a strong 
affirmation about possible associated autoantibody specifici-
ties. The strength of the relationship between a given immu-
nofluorescence pattern and the associated autoantibodies 
varies. 
Great emphasis has been given to the distinctive HEp-2 
ANA patterns in which there is staining of the mitotic plates. 
Since chromatin, the very substance of chromosomes, is a 
major target of SLE associated autoantibodies (anti-native 
DNA, anti-nucleosome, anti-histones), patterns circling the 
whole nucleus and the metaphase plate might be interpreted 
as indicative of anti-chromatin or anti-native DNA antibodies. 
However, morphological nuances disclose a heterogeneous 
scenario. A smooth hyaline staining of the mitotic plates and 
a homogeneous staining of the interphase nucleus are in 
fact compatible with anti-native DNA and anti-nucleosome 
antibodies. In contrast, a dense fine speckled staining of the 
interphase nucleus and a dense coarse staining of the mi-
totic plates are compatible with anti-DFS70/LEDGF antibodies 
(10,11). The first pattern indicates a strong possibility of SLE 
and the second pattern almost discards this diagnosis.6,12 
The relationship between HEp-2 ANA patterns and specific 
autoantibodies achieves a high degree of reliability in com-
plex patterns. For example, autoantigen distribution occurs in 
more than one cell compartment in such a dynamic and pe-
culiar fashion throughout the cell cycle that makes it virtually 
unique to that autoantigen. Since very few macromolecules 
share the same “cellular choreography”, very specific associa-
tions can be observed. Examples of such situation include the 
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centromere pattern,13 the proliferating cell nuclear antigen 
(PCNA) pattern (14), the NuMA-1 and NuMA-2 patterns,15,16 the 
CENP-F pattern,17 and the Scl-70 pattern.18 
The importance of the correct evaluation and classification 
of the several HEp-2 ANA patterns was soon acknowledged by 
several specialists in our country. The first Brazilian Consen-
sus on HEp-2 ANA Pattern took place in the year 2000,19 by ini-
tiative of Paulo Francescantonio, from Universidade Católica 
de Goiás, under the stimulus of Paulo Leser, from Escola Pau-
lista de Medicina. Thereafter, three editions of the Brazilian 
Consensus have taken place, each one advancing and com-
plementing the achievements of the previous editions.20-22 In 
each edition, several specialists from academic and private 
laboratories discuss thoroughly several aspects, including the 
definition, nomenclature, immunological associations, and 
clinical relevance of the several HEp-2 ANA patterns. Every 
edition has issued a final document approved by all partic-
ipants, all of which have been widely publicized in diverse 
media. The recommendations of the Consensus Group have 
been adopted by the majority of clinical and university labo-
ratories in the country. Interested clinicians have had access 
to this information via scientific articles, websites, and lec-
tures. The broadcast of the Consensus recommendations has 
largely contributed to improve the ability in the interpreta-
tion and characterization of the several HEp-2 ANA patterns 
by analysts across the country. This issue of Revista Brasileira 
de Reumatologia brings the proceedings of the fourth Brazil-
ian Consensus on HEp-2 ANA Pattern, occurred at the XXIX 
Brazilian Congress of Rheumatology in 2012 in Vitoria. In ad-
dition to important discussions regarding critical aspects in 
the methodology for determination of autoantibodies, novel 
HEp-2 ANA patterns were characterized and incorporated 
into the classification algorithm.
Related initiatives have been undertaken in different 
parts of the world. The French initiative, published in 2005, 
reports the progressive improvement and harmonization in 
the methodology for the execution of the assay, as well as 
for titer and pattern report by over 600 laboratories across 
the country.23 Only nuclear patterns were considered: ho-
mogenous, speckled, and centromeres. The German initia-
tive emphasized the technical recommendations for assay 
performance and considered seven nuclear patterns (nu-
cleolus was considered a type of nuclear pattern) and four 
cytoplasmic patterns. The recommendations were published 
in 2009, including a detailed and ingenious proposition to 
associate HEp-2 ANA patterns, autoantibody specificities 
and potential diseases.24 The North European initiative is the 
one that has the most similarities with the Brazilian Con-
sensus. Specialists from the Denmark, United Kingdom, and 
Sweden are involved in this initiative. Its recommendations 
were published in 2010 and offer an extremely detailed ar-
ray of nuclear, nucleolar, cytoplasmic, and mitotic apparatus 
patterns. High quality pictures are available for each pat-
tern, and associations between autoantibody specificities 
and clinical associations are established.25 Most recently, the 
Argentinian initiative has been published and addresses a 
carefully organized algorithm that has large resemblance to 
the Brazilian Consensus.26 
These independent initiatives in several countries reflect 
the importance of the subject. In addition it reflects the con-
cern of specialists for the need to match the information pro-
vided by the analysis in charge of the HEp-2 ANA test. In fact, 
these several isolated initiatives indicate that the time has 
come to build a World Consensus on ANA Pattern. This ob-
servation has been taken into account by the Autoantibody 
Standardization Committee, along with the International 
Union of Immunology Societies(IUIS) and the World Health 
Organization (WHO). Accordingly, the Autoantibody Standard-
izing Committee has commissioned the 12th International 
Workshop on Autoantibodies and Autoimmunity (IWAA) to 
implement the International Consensus on an ANA Patterns 
(ICAP) workshop. With the participation of renowned special-
ists from all over the world, the ICAP will take place during 
the first day of the 12th IWAA, which will occur in São Paulo 
from August 28th to 30th 2014. This will be a landmark event 
that shall pave the way for significant improvement in the 
serological diagnosis of systemic autoimmune diseases.
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Erratum
There is an error on the year on the headings of issue 1 of volume 54 
of Brazilian Journal of Rheumatology: in all pages, where it reads: REV 
BRAS REUMATOL 2013;54(1): and the number of the pages, it should 
read: REV BRAS REUMATOL 2014;54(1): and the number of the pages
R E F E R E N C E S
1. Tan EM. Autoantibodies to nuclear antigens (ANA): their 
immunobiology and medicine. Adv Immunol 1982; 33:167-240.
2. Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based 
guidelines for the use of immunologic tests: antinuclear 
antibody testing. Arthritis Rheum 2002; 47(4):434-44.
3. Waaler E. On the occurrence of a factor in human serum 
activating the specific agglutination of sheep corpuscles. 
Acta Pathol Microbiol Scand 1940; 17(2):172-88.
4. Hargraves M, Richmond H, Morton R. Presentation of two 
bone marrow components, the tart cell and the LE cell. 
Mayo Clin Proc 1948; 23(2):25-8.
5. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield 
NF et al: The 1982 revised criteria for the classification 
of systemic lupus erythematosus. Arthritis Rheum 1982; 
25(11):1271–7.
6. Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance 
A, Andrade LE. Pattern on the antinuclear antibody-HEp-2 
test is a critical parameter for discriminating antinuclear 
antibody-positive healthy individuals and patients with 
autoimmune rheumatic diseases. Arthritis Rheum 2011; 
63(1):191–200.
7. Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD et al: 
Prevalence and sociodemographic correlates of antinuclear 
antibodies in the United States. Arthritis Rheum 2012; 
64(7):2319-27.
8. Abeles AM, Abeles M. The clinical utility of a positive 
antinuclear antibody test result. Am J Med 2013;126(4):342-8.
9. Meroni PL, Chan EK, Tincani A, García de la Torre I, 
Andrade LE: Antinuclear antibody test: when to order? 
6 R E V  B R A S  R E U M A T O L .  2 0 1 4 ; 5 4 ( 1 ) : 3 – 6
Am J Med. 2013 126(10):e17. http://dx.doi.org/ 10.1016/j.
amjmed.2013.04.022
10. Ochs RL, Stein TW Jr, Peebles CL, Gittes RF, Tan EM. 
Autoantibodies in interstitial cystitis. J Urol 1994;151(3):587-
92.
11. Dellavance A, Viana VS, Leon EP, Bonfa ES, Andrade LE, Leser 
PG. The clinical spectrum of antinuclear antibodies associated 
with the nuclear dense fine speckled immunofluorescence 
pattern. J Rheumatol 2005; 32(11):2144-9.
12. Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, 
Carbone Y, et al. Anti-DFS70/LEDGF antibodies are more 
prevalent in healthy individuals compared to patients with 
systemic autoimmune rheumatic diseases. J Rheumatol 
2012;39(11):2104-10.
13. Moroi Y, Peebles C, Fritzler MJ, Steigerwald J, Tan EM. 
Autoantibodies to centromere (kinetochore) in scleroderma 
sera. Proc Natl Acad Sci USA 1980; 77(3):1627-31.
14. Takasaki Y, Fishwild D, Tan EM. Characterization 
of proliferating cell nuclear antigen recognized by 
autoantibodies in lupus sera. J Exp Med 1984;159(4):981-92.
15. Andrade LE, Chan EK, Peebles CL, Tan EM. Two major 
autoantigen-antibody systems of the mitotic spindle 
apparatus. Arthritis Rheum 1996; 39 (10):1643-53.
16. Whitehead CM, Winkfein RJ, Fritzler MJ, Rattner JB. The 
spindle kinesin-like protein HsEg5 is an autoantigen 
in systemic lupus erythematosus. Arthritis Rheum 
1996;39(10):1635-42.
17. Casiano CA, Humbel RL, Peebles C, Covini G, Tan EM. 
Autoimmunity to the cell cycle-dependent centromere 
protein p330d/CENP-F in disorders associated with cell 
proliferation. J Autoimmun 1995; 8(4):575-86.
18. Dellavance A, Gallindo C, Soares MG, da Silva NP, 
Mortara RA, Andrade LE. Redefining the Scl-70 indirect 
immunofluorescence pattern: autoantibodies to 
DNA topoisomerase I yield a specific compound 
immunofluorescence pattern. Rheumatology (Oxford, 
England) 2009;48(6):632–7.
19. Dellavance A. Gabriel Jr A, Cintra AFU, Ximenes AC, 
Nuccitelli B, von Mühlen CA et al. The first Brazilian 
Consensus for Standardization of ANA in HEp-2 cells. J Bras 
Patol Med Lab 2002; 38(3):207-16.
20. Dellavance A, Gabriel Jr G, Cintra AFU, Ximenes AC, 
Nuccitelli B, Taliberti BH et al. II Brazilian Consensus on 
Antinuclear Antibodies in HEp-2 Cells. Definitions for 
standardization of autoantibody testing against the nucleus 
(ANA HEp-2), nucleolus, cytoplasm, and mitotic apparatus, 
as well as its clinical associations. Rev Bras Reumatol 
2003;43(3):129-40.
21. Dellavance A, Gabriel Jr A, Nuccitelli B, Taliberti BH, von 
Mühlen CA, Bichara CDA et al. Third Brazilian Consensus 
for autoantibodies screening in HEp-2 cells (ANA). 
Recommendations for standardization of the autoantibody 
testing in HEp-2 cells, quality control, and clinical 
associations. Rev Bras Reumatol , 2009; 49(2):89–109.
22. Francescantonio PLC, Cruvinel WM, Andrade LEC, 
Dellavance A, Taliberti BH et al. IV Brazilian Guidelines for 
autoantibodies on HEp-2 cells. Rev Bras Reumatol 54: 44-50.
23. Pham BN, Albarede S, Guyard A, Burg E, Maisonneuve P. 
Impact of external quality assessment on antinuclear 
antibody detection performance. Lupus 2005;14(2):113-9.
24. Sack U, Conrad K, Csernok E, Frank I, Hiepe F, Krieger T, et al. 
Autoantibody detection using indirect immunofluorescence 
on HEp-2 cells. Ann N Y Acad Sci 2009;1173:166-73.
25. Carballo GO, Igénito FB, Ginaca AA, Carabajal P, Costa MA, 
Balbaryski J. First Argentine Consensus for standardization 
of Antinuclear Antibodies by Indirect Immunofluorescence–
HEp-2. Acta Bioquím Clín Latinoam 2012;46(1):3-13.
26. Wiik AS, Hoier-Madsen M, Forslid J, Charles P, Meyrowitsch 
J. Antinuclear antibodies: a contemporary nomenclature 
using HEp-2 cells. J Autoimmun 2010;35(3):276-90.
Luís Eduardo Coelho Andradea,b,c
a Rheumatology Division, Escola Paulista de Medicina, 
Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
b International Union of Immunology Societies (IUIS) 
c World Health Organization (WHO)
E-mail: rbreumatol@terra.com.br (L.E.C. Andrade).
